- Department of Neurosurgery, Aga Khan University Hospital, Karachi, Pakistan.
- Department of Neurosurgery, Ziauddin Medical University, Karachi, Pakistan.
Muhammad Waqas Saeed Baqai, Department of Neurosurgery, Aga Khan University Hospital, Karachi, Pakistan.
DOI:10.25259/SNI_976_2022Copyright: © 2023 Surgical Neurology International This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
How to cite this article: Muhammad Waqas Saeed Baqai1, Hafiza Fatima Aziz1, Saba Saleem Qazi2, Kunwer Sufyan Faisal2, Syed Muhammad Ismail Shah2. Glioblastoma imitating a cavernoma radiologically: A unique image report. 31-Mar-2023;14:112
How to cite this URL: Muhammad Waqas Saeed Baqai1, Hafiza Fatima Aziz1, Saba Saleem Qazi2, Kunwer Sufyan Faisal2, Syed Muhammad Ismail Shah2. Glioblastoma imitating a cavernoma radiologically: A unique image report. 31-Mar-2023;14:112. Available from: https://surgicalneurologyint.com/surgicalint-articles/12230/
Background: Glioblastoma is the most common primary malignant brain tumor with characteristic radiological features in most cases.
Case Description: We highlight an unusual case of a 54-year-old woman, neurologically intact, with a diagnostically challenging lesion. The patient’s magnetic resonance imaging revealed a left frontal lesion with surrounding edema and a hemosiderin ring, misleading it to be a cavernoma. Intraoperatively, the lesion was found to be a solid tumor with hematoma and was confirmed to be glioblastoma on histopathology.
Conclusion: The dilemma associated with our patient’s radiological findings and longstanding history of epilepsy is rare and a diagnostic challenge.
Keywords: Cavernoma, Epilepsy, Glioblastoma, Hemorrhage, IDH-1
Glioblastoma is the most common and malignant solid tumor of the brain, accounting for 57% of all gliomas and 48% of all primary central nervous system malignant tumors, with a median survival time of fewer than 2 years.[
Multiplanar and multisequential magnetic resonance imaging of the brain (a) T2WI hyperintense lesion with peripheral hemosiderin ring. (b)T1 without and with (c) contrast showed patchy enhancement on the lateral aspect. (d1) Fluid-attenuated inversion recovery (FLAIR) image surrounding edema noted at the medial aspect of the lesion. (d2) FLAIR image with punctate hyper-intensities in the left cortical region. (e) Susceptibility-weighted imaging lesion had diffuse signals drop-out (f and g). Diffusion-weighted imaging and apparent diffusion coefficient sequences showing diffusion restriction.
Therefore, to holistically appreciate glioblastoma progression, morphological and genetic alterations have been combined with traditional pathological descriptions of the disease to produce a dichotomous classification.[
A wide range of secondary neurological manifestations are associated with glioblastoma, including headaches, alteration in personality and cognition, gait imbalance, visual and olfactory disturbances, and epilepsy.[
A 54-year-old woman presented with complaints of transient right hand and arm numbness, along with facial twitching for 3 months. The patient had a 20-year history of epilepsy. Her neurological examinations were largely unremarkable.
On MRI [
Elective neuronavigation-guided craniotomy for maximus safe resection of the lesion was performed. Intraoperatively, it was noted to be an intra-axial soft to firm lesion with xanthrochromic discoloration throughout the lesion. Some abnormal vessels were difficult to coagulate; it was a clue that it could be a high-grade lesion rather than just a cavernoma.
The histopathological examination revealed neoplastic glial cells with hyperchromatic nuclei, inconspicuous nucleoli, and a moderate amount of eosinophilic cytoplasm. Multiple gemistocytes and areas of palisading tumor necrosis alongside areas of mitoses were seen. However, no microvascular proliferation was appreciated. Genetic analysis revealed that glial fibrillary acidic protein (GFAP) was positive, p53 and IDH-1 were both wild types, SOX10 and Cytokeratin AE1/ AE3 (CKAE1/AE3) were negative, and Ki67 index was 20%. The patient was thus diagnosed with glioblastoma, IDH-1 wild type [
Histopathology of glioblastoma multiforme. (a) H&E staining showed neoplastic cells with hyperchromatic nuclei and inconspicuous nucleoli with moderate amounts of eosinophilic cytoplasm. Multiple gemistocytes and areas of palisading tumor necrosis are also seen in the background. (b) Isocitrate dehydrogenase immunohistochemical staining negative for IDH mutation.
To effectively grasp the oddity that the radiographic image of this patient presents, the differences between cerebral cavernous malformations (CCMs) and glioblastoma on MRI must be accurately delineated.
CCMs or cavernomas are vascular abnormalities of the brain primarily composed of a collection of irregular, hyalinized capillaries circumscribed within a gliotic margin showing hemosiderin deposits.[
On a genetic basis, it is well documented in the literature that IDH-1 mutations are frequently observed in what was previously defined as “secondary” Glioblastoma (73– 85%),[
Thus, it is clear that the case we present is unique in relation to currently published literature on the subject, as not only did our patient’s Glioblastoma present as a mimetic CCM, her 20-year long history of epilepsy (which, according to the epidemiological data above, puts her below the mean age) points to her affliction being a lower-grade glioma primarily, which then progressed into a glioblastoma; however, the molecular profile of the patient signifies the development of a de novo glioblastoma, due to the absence of an IDH-1 mutation. Similarly, a consistent association of increased serum GFAP concentration has been seen in relation to the development of IDH-1 wild-type Glioblastoma,[
Due to the hemorrhage superimposing our patient’s glioblastoma, the lesion bore close resemblance, radiologically, to a cavernoma. In addition, IDH-1 wild-type glioblastoma predominantly manifests in older patients (>55). Existing literature and nomenclature-defining guidelines have shown that they are diagnosed only if specific genetic, molecular, and histopathological factors are present. The distinct nature of our case is predicated on the fact that, not only did our patient present with a rare case of mimicry, superimposed on this was an opposing epidemiological profile to IDH-1 wild-type glioblastoma, related closer to IDH-1 mutant glioblastoma while her other parameters were diametrically opposed; a situation distinctly unique within published literature on the subject.
The Institutional Review Board (IRB) permission obtained for the study.
There are no conflicts of interest.
The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Journal or its management. The information contained in this article should not be considered to be medical advice; patients should consult their own physicians for advice as to their specific medical needs.
Prof. Syed Ather Enam.
1. Boschi A, Consoli A, Buccoliero A, Barbagli G, Mangiafico S, Ammannati F. Left deep frontal cavernous angioma mimicking a glioma in an adult patient. Asian J Neurosurg. 2018. 13: 12-5
2. Broka A, Hysenaj Z, Sharma S, Rehmani R. Lion in sheep’s clothing: Glioblastoma mimicking intracranial hemorrhage. Cureus. 2021. 13: 14212
3. Hernández A, Domènech M, Muñoz-Mármol AM, Carrato C, Balana C. Glioblastoma: Relationship between metabolism and immunosuppressive microenvironment. Cells. 2021. 10: 3529
4. Jelski W, Mroczko B. Molecular and circulating biomarkers of brain tumors. Int J Mol Sci. 2021. 22: 7039
5. Kiviniemi A, Gardberg M, Frantzén J, Parkkola R, Vuorinen V, Pesola M. Serum levels of GFAP and EGFR in primary and recurrent high-grade gliomas: Correlation to tumor volume, molecular markers, and progression-free survival. J Neurooncol. 2015. 124: 237-45
6. Lange F, Hörnschemeyer J, Kirschstein T. Glutamatergic mechanisms in glioblastoma and tumor-associated epilepsy. Cells. 2021. 10: 1226
7. Li J, Zhang Y, Zuo H. Cerebral glioblastoma mimicking a cavernous malformation: A case report and literature review. Transl Neurosci Clin. 2017. 3: 35-9
8. Lote K, Stenwig AE, Skullerud K, Hirschberg H. Prevalence and prognostic significance of epilepsy in patients with gliomas. Eur J Cancer. 1998. 34: 98-102
9. Louis DN, Perry A, Reifenberger G, Von Deimling A, FigarellaBranger D, Cavenee WK. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 2016. 131: 803-20
10. Mouchtouris N, Chalouhi N, Chitale A, Starke RM, Tjoumakaris SI, Rosenwasser RH. Management of cerebral cavernous malformations: From diagnosis to treatment. ScientificWorldJournal. 2015. 2015: 808314
11. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009. 15: 6002-7
12. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: A clinical review. JAMA. 2013. 310: 1842-50
13. Prajapati HP, Singh DK. Recurrent glioblastoma in elderly: Options and decision for the treatment. Surg Neurol Int. 2022. 13: 397
14. Prajapati HP, Ansari A. Updates in the management of recurrent glioblastoma multiforme. J Neurol Surg A Cent Eur Neurosurg. 2023. 84: 174-87
15. Sokratous G, Ughratdar I, Selway R, Al-Sarraj S, Ashkan K. Cavernoma: New insights from an unusual Case. World Neurosurg. 2017. 102: 696.e7-696.e11
16. Wilson DM, Cohen B, Keshari K, Vogel H, Steinberg G, Dillon W. Case report: Glioblastoma multiforme complicating familial cavernous malformations. Clin Neuroradiol. 2014. 24: 293-6
17. Yang K, Wu Z, Zhang H, Zhang N, Wu W, Wang Z. Glioma targeted therapy: Insight into future of molecular approaches. Mol Cancer. 2022. 21: 39